Intensive systolic blood pressure control and prevention of new onset atrial fibrillation in the SPRINT study: is the association really controversial?

References

• Parcha V, Patel N, Kalra R, et al. Incidence and implications of atrial fibrillation/flutter in hypertension insights from the SPRINT Trial. Hypertension. 2020;75(6):1483–1490.
   PubMed Web of Science ®Google Scholar
• Soliman EZ, Rahman A, Zhang Z, et al. Effect of intensive blood pressure lowering on the risk of atrial fibrillation. Hypertension. 2020;75(6):1491–1496.
   PubMed Web of Science ®Google Scholar
• Ambrosius WT, Sink KM, Foy CG, et al. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: The Systolic Blood Pressure Intervention Trial (SPRINT). Clin Trials. 2014;11(5):532–546.
   PubMed Web of Science ®Google Scholar
• Wright JT, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103–2116.
   PubMed Web of Science ®Google Scholar
• Kjeldsen SE, Oparil S, Narkiewicz K, et al. The J-curve phenomenon revisited again: SPRINT outcomes favor target systolic blood pressure below 120 mmHg. Blood Press. 2016;25(1):1–3.
   PubMed Web of Science ®Google Scholar
• Burnier M, Oparil S, Narkiewicz K, et al. New 2017 American Heart Association and American College of Cardiology guideline for hypertension in the adults: major paradigm shifts, but will they help to fight against the hypertension disease burden? Blood Press. 2018;27(2):62–65.
   PubMed Web of Science ®Google Scholar
• Grundvold I, Skretteberg PT, Liestøl K, et al. Upper normal blood pressures predict incident atrial fibrillation in healthy middle-aged men. A 35 year follow-up study. Hypertension. 2012;59(2):198–204.
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Dagenais G, Healey J, et al. Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease studies. J Hypertens. 2012;30:1004–1014.
   PubMed Web of Science ®Google Scholar
• Manolis AJ, Agabiti Rosei E, Coca A, et al. Hypertension and atrial fibrillation: diagnostic approach, prevention and treatment. Position paper of the Working Group ‘Hypertension Arrhythmias and Thrombosis’ of the European Society of Hypertension. J Hypertens. 2012;30(2):239–252.
   PubMed Web of Science ®Google Scholar
• Wachtell K, Hornestam B, Lehto M, et al. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 2005;45(5):705–711.
   PubMed Web of Science ®Google Scholar
• Okin PM, Wachtell K, Devereux RB, et al. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA. 2006;296(10):1242–1248.
   PubMed Web of Science ®Google Scholar
• Wachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillationand subsequent stroke compared to atenolol. The losartan intervention for end point reduction in hypertension (LIFE) Study. JACC. 2005;45(5):712–719.
   Google Scholar
• Gerdts E, Wachtell K, Omvik P, at al. Left atrial size and risk of major cardiovascular events during antihypertensive treatment: losartan intervention for endpoint reduction in hypertension trial. Hypertension. 2007;49(2):311–316.
   PubMed Web of Science ®Google Scholar
• Wachtell K, Gerdts E, Aurigemma GP, et al. In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: the LIFE Study. Blood Press. 2010;19(3):169–175.
   PubMed Web of Science ®Google Scholar
• Larstorp AC, Ariansen I, Gjesdal K, et al. Association of pulse pressure with new-onset atrial fibrillation in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint (LIFE) reduction in hypertension study. Hypertension. 2012;60(2):347–353.
   PubMed Web of Science ®Google Scholar
• Shaikh AY, Wang N, Yin X, et al. Relations of arterial stiffness and brachial flow-mediated dilation with new-onset atrial fibrillation: the Framingham Heart Study. Hypertension. 2016;68(3):590–596.
   PubMed Web of Science ®Google Scholar
• Aksnes TA, Schmieder RE, Kjeldsen SE, et al. Impact of new-onset DM on atrial fibrillation and heart failure development in high risk hypertension (from the VALUE trial). Am J Cardiol. 2008;101(5):634–638.
   PubMed Web of Science ®Google Scholar
• Schmieder RE, Kjeldsen SE, Julius S, et al. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. J Hypertens. 2008;26(3):403–411.
   PubMed Web of Science ®Google Scholar
• Zhang W, Wang J-G. Prevention of atrial fibrillation by intensive antihypertensive treatment. Hypertension. 2020;75(6):1414–1416.
   PubMed Web of Science ®Google Scholar
• Chen LY, Bigger JT, Hickey KT, et al. Effect of intensive blood pressure lowering on incident atrial fibrillation and P-wave indices in the ACCORD blood pressure trial. Am J Hypertens. 2016;29(11):1276–1282.
   Google Scholar
• Vagaonescu TD, Wilson AC, Kostis JB. Atrial fibrillation and isolated systolic hypertension: the Systolic Hypertension in the Elderly Program and Systolic Hypertension in the Elderly Program-extension study. Hypertension. 2008;51(6):1552–1556.
   PubMed Web of Science ®Google Scholar
• Okin PM, Hille DA, Larstorp ACK, et al. Effect of lower on-treatment systolic blood pressure on the risk of atrial fibrillation in hypertensive patients. Hypertension. 2015;66(2):368–373.
   PubMed Web of Science ®Google Scholar
• Dewland TA, Soliman EZ, Yamal JM, et al. Pharmacologic prevention of incident atrial fibrillation: long-term results from the ALLHAT (antihypertensive and lipid-lowering treatment to prevent heart attack trial). Circ Arrhythm Electrophysiol. 2017;10(12):e005463.
   PubMed Web of Science ®Google Scholar
• Larstorp ACK, Stokke IM, Kjeldsen SE, et al. Antihypertensive therapy prevents new-onset atrial fibrillation in patients with isolated systolic hypertension: the LIFE study. Blood Press. 2019;28(5):317–326.
   PubMed Web of Science ®Google Scholar
• Williams B, Mancia G, Spiering W, et al. 2018 Practice guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. Blood Press. 2018;27(6):314–340.
   PubMed Web of Science ®Google Scholar
• Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):1269–1324.
   PubMed Web of Science ®Google Scholar